David Maris - Wells Fargo


Last quote by David Maris

Zilretta ... has the potential to be a gamechanger in osteoarthritis knee pain treatment.feedback
share this quote
Oct 06 2017
We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which David Maris is associated, including Allergan, Pfizer, and pricing. Most recently, David Maris has been quoted saying: “They've only had bad news in the generic industry recently, and now you have a little bright news here with a key win for Mylan. Gives with one he can take away with another. One thing to keep in mind is a complex generic like EpiPen, there's no AB rated, non-Mylan generic out there. That could be one of the things he targets next.” in the article Mylan's move higher after FDA approval 'a little bit exaggerated, ' says Wells Fargo analyst.
Automatically powered by Storyzy
Take our quote verification challenge and find out !

David Maris quotes

Apr 11 2017

When something reaches a warning letter stage, it can show that the FDA is dissatisfied with the company's attempts to explain or remediate the issue.feedback

Mar 14 2017

With ... one of its most vocal supporters selling its stake near the low for the past 10 years, we see this as a vote of no confidence for the stock and that things are continuing to go from bad to worse for Valeant.feedback

Mar 14 2017

There has to be restraint, but there also has to be responsibility.feedback

Nov 08 2016

It's a complete zero.feedback

Nov 04 2016

The pharmaceutical industry actually spends more in R&D than both the aerospace and the tech industry combined. So you go after these, what might happen is … fewer innovations.feedback

Oct 10 2016

We think investors will like the settlement as many will think this puts the issue largely behind the company – we disagree as this only addresses the CMS portion of this – it does nothing to answer the original issue – EpiPen pricing and customers.feedback

Oct 10 2016

We believe the issues of antitrust and potential SEC issues may linger.feedback

Oct 10 2016

While some legislators may at first blush exclaim that the government has done its job in extracting some financial arrangement, we do not believe that this will be the end of the debate, as consumers will not see any of the money coming from the CMS/DOJ resolution.feedback

Sep 08 2016

Everyone understands that drug companies should make a little bit more each year; that their costs go up. Their people have to get paid more. Science costs more to do. But if we could limit maybe the outliers.feedback

Sep 08 2016

I don't think that having government run that process is really the right way, because it's a Trojan horse for price controls. Once they start controlling a little bit of price, then the temptation is to control all of price, and if you do that, you really get fewer drugs invented.feedback

Jun 10 2016

We believe that given the regulatory environment, these pricing actions could bring greater regulatory scrutiny and headline risk. Additionally, we wonder if aggressive price increases are being used to make EPS targets or to offset disappointing sales in other areas.feedback

Apr 05 2016

To us, whether Pfizer and Allergan stay committed will be known shortly–more important for many is if the deal breaks, where should Allergan trade?feedback

No quotes...
More David Maris quotes
|< <
> >|

Quotes by David Maris

Quote Verifier
Check if the quote you read on social networks is authentic
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided

Quote :

Mistake :

Comments :